Evidence map›Paper›PMID 28744736›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2018

Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.

Douglas Tremblay, Vaibhav Patel, Kenneth M Fifer, Jessica Caro, Olivia Kolodka, John Mandelli, Charles L Shapiro

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Douglas TremblayDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Vaibhav PatelDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kenneth M FiferDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jessica CaroDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Olivia KolodkaDubin Breast Center, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, PO Box 1079, New York, NY, 10029, USA.
John MandelliDepartment of Environmental Medicine and Public Health, Icahn School of Medicine at Mt Sinai, New York, NY, USA.
Charles L ShapiroDubin Breast Center, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, PO Box 1079, New York, NY, 10029, USA. Charles.Shapiro@mssm.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAromatase inhibitors (AIs) are the preferred therapy for postmenopausal women with early-stage estrogen receptor-positive breast cancers. However, their use causes bone loss and increased risks of osteoporosis and fractures.

methodsThis is a retrospective review of all postmenopausal women with breast cancer diagnosed and treated with AI between 2010 and 2015. Of the 564 women identified, 319 were eligible.

resultsThe median age at AI initiation was 65 years (range 51-85 years), and the median duration of AI therapy was 28 months (1-72 months). The median number of DEXA scans per woman was 1 (0-4), performed at a median frequency of 24 months (1-48 months). Recommendations for calcium and vitamin D were in 66 and 59% of women, respectively. There were 52 (16%) women who received antiresorptive treatments with bisphosphonates (69%), denosumab (25%), or both drugs (6%). Based on guideline recommendations from six societies, starting antiresorptive treatment was unnecessary in 15-54% of women.

conclusionsIn this single health system experience, women start antiresorptive drugs that are unnecessary in 15-52%. These results highlight the nonuniformity in guideline recommendations, and this has implications for quality of care, cost-effectiveness, and value-of-care analyses for preventing fractures.

Indexed as

AgedAged, 80 and overAromatase InhibitorsBone DensityBone Density Conservation AgentsBreast NeoplasmsCalcium, DietaryDenosumabDiphosphonatesFemaleFractures, BoneHumansMiddle AgedOsteoporosis, PostmenopausalRetrospective StudiesVitamin DAromatase InhibitorsBone Density Conservation AgentsCalcium, DietaryDenosumabDiphosphonatesVitamin DAntiresorptive drugsAntiresorptive therapiesAromatase inhibitorsVitamin D

Identifiers

PMID28744736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.